Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 36%
Sell 7%
Strong Sell 0%

Bulls say

Incyte's strong financial outlook is bolstered by a 10% year-over-year demand growth for its leading drug, Jakafi, across various indications, which is supported by solid commercial execution and a favorable partnership with Novartis. The firm's dermatology product, Opzelura, demonstrated impressive growth with revenue of $188 million, surpassing expectations, as demand for treatments in atopic dermatitis and vitiligo increased significantly. Incyte's revised fiscal year 2025 revenue guidance, now projected between $4.23 billion and $4.32 billion, reflects positive contributions from Jakafi and other oncology products, indicating a robust overall pipeline and market position.

Bears say

Incyte faces significant risks that contribute to a negative outlook on its stock, particularly related to its leading drug, Jakafi. Eroding pricing power, potential competition, and performance issues in earlier-stage pipeline products could adversely impact revenue growth and market share. Additionally, any clinical or regulatory setbacks, as well as safety concerns related to existing and new therapies, may further diminish investor confidence and future earnings potential.

Incyte (INCY) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 36% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 14 analysts, Incyte (INCY) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.